FIELD: chemistry.
SUBSTANCE: invention relates to the use of a compound selected from inositol monophosphate (IP1), inositol diphosphate (IP2), inositol triphosphate (IP3), inositol tetraphosphate (IP4), inositol pentaphosphate (IP5) and inositol hexaphosphate (IP6), including myo-inositol hexaphosphate, or a pharmaceutically acceptable salt thereof, or a composition containing such a compound, for treating, slowing progression or preventing calcification aortic valve in a human subject in need thereof.
EFFECT: applied compound is in a form suitable for parenteral, local or enteral administration, and is administered in a non-polar form with prolonged release in an effective dosage of about 200 mg to about 700 mg per administration.
19 cl, 12 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF DERIVATIVES CONTAINING THE C-O-P BONDS IN THE PATIENTS WITH RENAL INSUFFICIENCY | 2014 |
|
RU2725626C2 |
| COMPOSITION, CONTAINING CRYSTALLISATION-INHIBITING SUBSTANCES | 2009 |
|
RU2535094C2 |
| FIXED COMBINATIONS AND COMPOUNDS CONTAINING ETC-1002 AND EZETIMIBE, AND METHOD FOR TREATING OR REDUCING THE RISK OF DEVELOPING A CARDIOVASCULAR DISEASE | 2016 |
|
RU2766085C2 |
| COMPOSITIONS AND METHODS FOR REDUCING SERIOUS ADVERSE CARDIOVASCULAR EVENTS | 2014 |
|
RU2711638C2 |
| FIXED COMBINATIONS AND COMPOSITIONS CONTAINING ETC1002 AND ONE OR MORE STATINS, AND METHODS FOR TREATMENT OR REDUCTION IN RISK OF DEVELOPMENT OF CARDIOVASCULAR DISEASE | 2016 |
|
RU2765218C2 |
| COMPOSITIONS CONTAINING DPP-4 INHIBITOR FOR PREVENTION OR TREATMENT OF VALVE CALCIFICATION | 2015 |
|
RU2680527C1 |
| 1-METHYLNIKOTINAMIDE USE FOR TREATMENT OF DISEASES ASSOCIATED WITH C-REACTIVE PROTEIN | 2017 |
|
RU2744615C2 |
| NEUROACTIVE STEROIDS, COMPOSITIONS AND APPLICATIONS THEREOF | 2017 |
|
RU2766155C2 |
| TREATMENT OF HEART FAILURE IN HUMANS | 2020 |
|
RU2811365C2 |
| ALPHA-1 PROTEINASE INHIBITOR FOR DELAY OF BEGINNING OR PROGRESS OF PULMONARY EXACERBATIONS | 2012 |
|
RU2635482C2 |
